Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

SIMPLE SUMMARY: Using a randomized discontinuation design, sorafenib was tested on patients with advanced/metastatic solid tumors previously treated by standard treatments and harboring sorafenib-targeted genes. Patients with stable disease after 12 weeks of sorafenib induction treatment were random...

Descripción completa

Detalles Bibliográficos
Autores principales: Trédan, Olivier, Toulmonde, Maud, Le Tourneau, Christophe, Montane, Laure, Italiano, Antoine, Ray-Coquard, Isabelle, De La Fouchardière, Christelle, Bertucci, François, Gonçalves, Anthony, Gomez-Roca, Carlos, You, Benoit, Attignon, Valéry, Boyault, Sandrine, Cassier, Philippe A., Dufresne, Armelle, Tabone-Eglinger, Séverine, Viari, Alain, Sohier, Emilie, Kamal, Maud, Garin, Gwenaël, Blay, Jean-Yves, Pérol, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340237/
https://www.ncbi.nlm.nih.gov/pubmed/37444551
http://dx.doi.org/10.3390/cancers15133441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340237/
https://www.ncbi.nlm.nih.gov/pubmed/37444551
http://dx.doi.org/10.3390/cancers15133441

Ejemplares similares